Line 80: | Line 80: | ||
<h1>Current solutions for rapid testing</h1> | <h1>Current solutions for rapid testing</h1> | ||
<p> | <p> | ||
− | Most point-of-care tests that are currently established on the market, like pregnancy tests, are based on antibodies targeting certain metabolites. These tests are therefore restricted to one specific application and require long and expensive design cycles for the development of new tests for other applications or changing pathogen epitopes as in case of endemic virus strains with high mutation rate. | + | Most point-of-care tests that are currently established on the market, like pregnancy tests, are based on antibodies targeting certain metabolites<sup><a class="myLink" href="#ref_4">4</a></sup>. These tests are therefore restricted to one specific application and require long and expensive design cycles for the development of new tests for other applications or changing pathogen epitopes as in case of endemic virus strains with high mutation rate. |
<p> | <p> | ||
− | According to our contact person at Médecins Sans Frontières (<a class="myLink" href="http://msf.org">MSF</a>), already existing low-cost POC-test for infectious diseases are mostly based on antibody-based lateral flow tests such as | + | According to our contact person at Médecins Sans Frontières (<a class="myLink" href="http://msf.org">MSF</a>), already existing low-cost POC-test for infectious diseases are mostly based on antibody-based lateral flow tests such as <a class="myLink" href="http://www.biomerieux-diagnostics.com/bionexia-rota-adeno-rapid-test">BIONEXIA® Rota Adeno</a> or <a class="myLink" href="http://nhdiag.com/cholera_bt.shtml">SMART™II Cholera O1</a>. Recently, qPCR-based systems were developed that provide a more universal solution for highly automated nucleic-acid detection. According to our contact person at MSF, also cartridge-based systems are currently employed as POC diagnostics for in-field applications. <a class="myLink" href="http://www.cepheid.com/us/cepheid-solutions/systems/genexpert-systems/genexpert-iv">GeneXpert</a> allows the detection of MRSA in patient samples, and <a class="myLink" href="https://www.alere.com/en/home/search.html?searchtext=alereq&c=WW&%3Acq_csrf_token=undefined">Alere™ q</a> provides an automated bench top platform for nucleic acid testing in any healthcare setting. |
</p> | </p> | ||
<p> | <p> | ||
Line 143: | Line 143: | ||
<li id="ref_2">St John A, Price CP. Existing and Emerging Technologies for Point-of-Care Testing. <i>Clin Biochem Rev.</i> 2014 Aug;35(3):155-67. PubMed PMID: 25336761; PubMed Central PMCID: PMC4204237.</li> | <li id="ref_2">St John A, Price CP. Existing and Emerging Technologies for Point-of-Care Testing. <i>Clin Biochem Rev.</i> 2014 Aug;35(3):155-67. PubMed PMID: 25336761; PubMed Central PMCID: PMC4204237.</li> | ||
<li id="ref_3">Llor, C., & Bjerrum, L. (2014). Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety, 5(6), 229–241. http://doi.org/10.1177/2042098614554919</li> | <li id="ref_3">Llor, C., & Bjerrum, L. (2014). Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety, 5(6), 229–241. http://doi.org/10.1177/2042098614554919</li> | ||
+ | <li id="ref_4">Peeling RW, McNerney R. Emerging technologies in point-of-care molecular diagnostics for resource-limited settings. Expert Rev Mol Diagn. 2014 Jun;14(5):525-34. PubMed PMID: 24784765.</li> | ||
+ | |||
</ol> | </ol> |
Revision as of 23:53, 1 November 2017
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|